GTC Biotherapeutics (fka GTCB)

[dewophile]

If that's possible - great. The IP would certainly take care of itself, and it's well known that enhanced glycosylation or modifying the sugars to include say more sialylation can alter kinetics. But what anotherbiotechguy mentioned, inserting a glycosylation signal sequence in the construct like what was done to epo to produce aranesp, might be an easier solution without the need for any sweeping change in GTCB's current production methods